What To Know
- Feldman's appointment directly relates to the leadership role Soleo Health has established in the specialty pharmaceutical limited drug distribution arena, based on the capabilities of its innovative and proprietary clinical outcomes program, SoleMetrics®.
- Feldman was vice president, specialty distribution for Two Labs Pharma Services, a leading pharmaceutical consulting company providing a portfolio of market access, market intelligence and commercialization services to manufacturers.
November 11, 2020
Elizabeth Feldman has been appointed Soleo Health VP Development, Industry Relations.
Elizabeth Feldman will be responsible for forging and maintaining relationships with pharmaceutical manufacturers to coincide with Soleo Health’s expertise and focus on caring for complex specialty patients with rare and ultra-rare diseases.
Feldman brings more than 15 years of experience working directly with pharmaceutical manufacturers to commercialize newly launched products across multiple specialty distribution channels to her new role. Feldman was vice president, specialty distribution for Two Labs Pharma Services, a leading pharmaceutical consulting company providing a portfolio of market access, market intelligence and commercialization services to manufacturers. In this capacity, she guided various emerging specialty pharmaceutical manufacturers in the efficient launch of their products while also developing channel strategies throughout the commercialization process.
Earlier, Feldman was vice president, business development and trade relations for ASD Healthcare, the specialty distribution arm for AmerisourceBergen Corp., a global leader in pharmaceutical distribution. She was responsible for overseeing the company’s portfolio of 200+ specialty pharmaceutical products. She secured 98% of drugs launched in the specialty market within a 12-month period, effectively negotiating early-stage commercialization discussions with established and emerging manufacturers — both large and small. Many of these relationships were part of either a limited or exclusive distribution network.
Feldman’s appointment directly relates to the leadership role Soleo Health has established in the specialty pharmaceutical limited drug distribution arena, based on the capabilities of its innovative and proprietary clinical outcomes program, SoleMetrics®. At the core of several limited distribution drug manufacturer relationships the Company has forged, SoleMetrics collects and delivers real-world, insightful data regarding a drug’s clinical capabilities, derived from its patients.
Feldman commented on her joining the Company: “Soleo Health has carved a distinct market niche for itself in the complex specialty pharmaceuticals space as well as within the limited drug distribution marketplace. My new position affords me the opportunity to cultivate new manufacturer relationships while also leveraging the strong ones I have built to further cement Soleo Health’s place in future specialty drug launches.
